At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09688 ZAI LAB
Not Yet Opened 05-15 16:09:05
16.090
+0.740
+4.82%
High16.160
Low15.350
Vol17.18M
Open15.760
D1 Closing15.350
Amplitude5.28%
Mkt Cap18.25B
Tradable Cap18.25B
Total Shares1.13B
T/O270.62M
T/O Rate1.51%
Tradable Shares1.13B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Zai Lab Chief Legal Officer Edmondson Titus III sells 3,517 shares for $71,019.23
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a Dll3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (Epnecs)
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.